The Inducible T Cell Costimulator pipeline drugs market research report outlays comprehensive information on the Inducible T Cell Costimulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Inducible T Cell Costimulator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Ophthalmology which include the indications Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes), and Uveitis. It also reviews key players involved in Inducible T Cell Costimulator targeted therapeutics development with respective active and dormant or discontinued products.
The Inducible T Cell Costimulator pipeline targets constitutes close to four molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, and Phase I stages are 3, and 1 respectively.
Inducible T Cell Costimulator overview
Inducible T Cell Costimulator enhances all basic T-cell responses to a foreign antigen, such as proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. It is essential for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. It prevents the apoptosis of pre-activated T-cells and plays a critical role in CD40-mediated class switching of immunoglobin isotypes.
For a complete picture of Inducible T Cell Costimulator’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
